Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.04 USD | -2.42% | -6.70% | -83.74% |
14/05 | Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform | MT |
10/05 | Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-83.74% | 14Cr | |
+9.42% | 11TCr | |
+11.84% | 11TCr | |
-1.05% | 2.2TCr | |
-14.15% | 2.19TCr | |
-5.29% | 1.92TCr | |
-4.16% | 1.81TCr | |
-38.29% | 1.77TCr | |
+7.99% | 1.43TCr | |
+36.24% | 1.24TCr |
- Stock Market
- Equities
- RAPT Stock
- News RAPT Therapeutics, Inc.
- JPMorgan Adjusts Price Target on RAPT Therapeutics to $42 From $48, Maintains Overweight Rating